

## ABSTRACT

64 The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human  
5 natural cytotoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.

20090907-1119001